GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCLIN.L Share News (CLIN)

  • There is currently no data for CLIN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Rockhopper rises as Navitas enters project

Wed, 08th Dec 2021 11:45

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

----------

AIM - WINNERS

----------

Rockhopper Exploration PLC, up 22% at 6.38 pence, 12-month range 4.50p-12.50p. The oil & gas exploration and production company says Navitas Petroleum LP is to enter its Sea Lion oil project in the Falkland Islands. Navitas replaces Harbour Energy PLC as Rockhopper's partner in the project.

----------

Equals Group PLC, up 12% at 70.40p, 12-month range 26.10p-73.00. The fintech payments firm says it has "significantly exceeded" its full-year expectations for both adjusted earnings and revenue. Group revenue for the year to date is GBP40.4 million, up 51% from GBP26.8 million for the same period in 2020. The strong revenue performance means increased gross profit and earnings, and Equals says it has exceeded its own full-year profitability forecasts, but does not provide a figure.

----------

Clinigen Group PLC, up 10% at 901.00p, 12-month range 541.50p-912.00p. Shares hit 12-month high after the pharmaceuticals and services provider agrees to be taken private by European investment firm Triton Funds in a GBP1.2 billion deal. Under the terms, Clinigen shareholders will receive 883p a share in cash. This is a 41% premium to the ex-dividend closing share price on December 1, which was the last business day before takeover talks were first announced. Clinigen shareholders will also be entitled to receive the previously declared final dividend of 5.46p a share.

----------

AIM - LOSERS

----------

Byotrol PLC, down 16% at 4.22p, 12-month range 4.00p-7.70p. Shares in the antimicrobial technologies company hit fresh 12-month low after profit warning and says its first half performance was below expectations. For six months to September 30, swings to pretax loss of GBP141,000 from GBP1.0 million profit year before. "Whilst we expect to be both profitable and cash generative in the second half of the year, with these uncertainties it is difficult to predict the quantum at this juncture. At present we are expecting IP sales to offset the majority of the anticipated shortfall in profit on product sale, but projecting the timing of IP sales is even more uncertain, so we feel it prudent to now reduce market guidance for the current financial year," it says.

----------

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
7 Nov 2016 16:05

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
30 Oct 2016 14:52

Sunday newspaper round-up: More 'Nissan' deals, Carney, RBS, HSBC, Capita

(ShareCast News) - Pharmaceuticals giants want the government to plug a £1bn-a-year funding gap that will be created when Britain leaves the EU, as part of a list of demands being drawn up by big business after last week's deal with Nissan. After the Japanese car maker said it would make two new mod

Read more
25 Oct 2016 08:50

Clinigen Group extends partnership with BTG

(ShareCast News) - AIM-listed pharmaceutical Clinigen Group's Idis Global Access division extended its four-year partnership with BTG, a healthcare company, to manage its critical care portfolio across the whole of Europe and new territories in Asia. The agreement now includes all of Europe and some

Read more
25 Oct 2016 06:37

Clinigen Group Extends Exclusive Supply Agreement With BTG

Read more
18 Oct 2016 08:36

Clinigen expands operations into Japan

(ShareCast News) - Clinigen Group, an AIM listed global pharmaceuticals and services company, has extended its geographical reach to Japan with the opening of a new office in Tokyo. Clinigen KK further expands the group's presence in Asia following the company's acquisition of Link healthcare in 201

Read more
18 Oct 2016 07:45

Clinigen Opens Tokyo Office To Take Foscavir Marketing Back In-House

Read more
5 Oct 2016 16:13

DIRECTOR DEALINGS SUMMARY: Clinigen Executive Slashes Shareholding

Read more
28 Sep 2016 09:43

WINNERS & LOSERS SUMMARY: UK Mail Jumps On Deutsche Post Cash Offer

Read more
22 Jul 2016 10:21

Clinigen Group issues 38k option shares

(ShareCast News) - Clinigen Group announced on Friday that it has made an application for the admission to trading on AIM of 38,308 ordinary shares of 0.1p each. The firm said the shares have been issued to satisfy the exercise of share options, and rank pari passu with the existing shares of the gr

Read more
20 Jul 2016 14:42

Clinigen revenue and profits see serious rise

(ShareCast News) - Global pharmaceutical and services company Clinigen Group posted a trading update for the year to 30 June on Wednesday, reporting an 87% improvement in revenue and a 90% increase in gross profit. The AIM-traded firm said the growth was driven primarily by acquisitions and organic

Read more
20 Jul 2016 09:47

WINNERS & LOSERS SUMMARY: Man Group Down As CEO Departs For PIMCO

Read more
20 Jul 2016 07:02

Clinigen Revenue And Profit Surge On Acquisitions, Organic Growth

Read more
13 Jul 2016 15:02

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
7 Jul 2016 15:27

Clinigen Group Issues 83,016 Shares In Option Exercise (ALLISS)

Read more
29 Jun 2016 12:20

Clinigen teams up with Horizon on RAVICTI

(ShareCast News) - Clinigen Group was celebrating on Wednesday, as its Idis Managed Access division and Nasdaq-traded Horizon Pharma initiated a Managed Access Programme in Europe for Horizon's RAVICTI oral liquid. The AIM-traded firm said RAVICTI received centralised marketing approval from the Eur

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.